New Antibiotic by Merck that Fights Bacteria
In today's landscape of drug discovery, only a limited number of pharmaceutical companies are investing in antibiotic research, as the majority prefer to focus on developing profitable drugs for chronic diseases. Unfortunately, many existing antibiotics have become less effective over time as bacteria have developed resistance to them, highlighting the urgent need for new solutions.
Merck, however, has made significant progress in this area by developing an antibiotic called platensimycin, which shows promise in combating bacteria such as MRSA that have become resistant to currently available antibiotics like oxazolidinone and streptogramin. This antibiotic works by inhibiting an enzyme called FabF, which is involved in the formation of fatty acids that serve as essential building blocks for bacterial cell membranes and surfaces.
To discover potential antibacterial compounds, the research team at Merck conducted an extensive screening process involving 250,000 natural compounds. Eventually, their efforts led them to platensimycin, a small molecule produced by a microorganism found in South Africa. This antibiotic has already undergone testing on mice, demonstrating no toxic effects. However, before it can be brought to the market, platensimycin will need to undergo further rigorous clinical trials and regulatory processes to ensure its safety and efficacy.
This breakthrough offers hope for the development of a new antibiotic to combat drug-resistant bacteria, although additional research and development are required to make it commercially viable
